5 Patient history may be obtained within 8 weeks prior to enroll ment. 6 ECOG of 0, 1, or 2. 7 After each vaccination, vital signs will be monitored hourly ( ± 15 minutes) for two hours. The post-administration monitoring period may be adjusted by the PI. 8 Serum or urine; on all females of child-bearing potential. Comp lete at all follow-up evaluations within 4 months after the last vaccine. 9 With culture if indicated. 10 HIV antibody titer, HBsAg determination, anti HCV, anti CMV a ntibody titer, HSV serology, and EBV panel. Patients who are kn own to be positive for CMV, HSV and/or EBV do not need to be retested. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 22AssessmentsScreening/Baseline (prior to enrollment on treatment protocol)On-Study/Course of Treatment (1 vaccine = 1 cycle)Post-Treatment Follow-up Within 3 MonthsWithin 4 WeeksWithin 7 DaysDay 01Day 14 (±5 d)Day 28 (±5 d)Day 42 (±5 d)Day 56 (±5 d)Subsequent Follow-up Visits2 CBC w/differential XX X X X X X Chemistry panel11XX X X X X X PT/PTT XX Lymphocyte phenotyping (TBNK) X XX Additional leukapheresis12X Correlatives13 CPT tubes (8) (SB CPF) XXXX X X SST tube (1) (Figg Lab) XXXX X X Imaging CT, MRI, PET, and/or photography14X XX Chest x-ray XX Treatment/Intervention Peptide loaded dendritic cell vaccine15XXXX 11 Chemistry panel: Sodium (Na), Potassium (K), Chloride (Cl), T otal CO2 (bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN ), Albumin, Calcium total, Magnesium total (Mg), Inorganic Phosphorus, Alkaline Phosphatas e, ALT/GPT, AST/GOT, Total Bilirubin, Direct Bilirubin, LD, Tot al Protein, Total CK, Uric Acid 12 A 5 liter leukapheresis may be performed. If the patient is un able to undergo leukapheresis, approximately 96 ml of blood may be obtained.